MustGrow Reports First Quarter 2025 Results, Achieving $3.8 Million in Sales Revenue

SASKATOON, Saskatchewan, Canada – May 27, 2025 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow”), a leading provider of biological and regenerative agriculture solutions, has announced its operating and financial results for the three months ended March 31, 2025.

For full details, stakeholders can refer to the Q1-2025 Condensed Interim Financial Statements and Management’s Discussion and Analysis available on SEDAR+ or the Company’s website: www.mustgrow.ca.

Key Financial Highlights:

• Sales revenue of $3.8 million was recorded in Q1-2025 vs. zero in Q1-2024
• Gross profit of $541,221 with a 14.3% gross profit margin in Q1-2025⁽¹⁾
• Cash and equivalents on hand as of March 31, 2025 totaled $2.0 million with Inventory of $2.4 million
• Net loss for the period was $1.6 million, or $0.03 per share (basic)

“Our 2025 first quarter marked a pivotal milestone for MustGrow, reflecting the first full quarter of revenue since the acquisition of the NexusBioAg sales and distribution business on December 31, 2024,” said Corey Giasson, President and CEO of MustGrow. “$3.8 million is a meaningful revenue figure for us, and with additional products already secured for the NexusBioAg distribution platform and increasing commercial farmer interest in our TerraSante™ U.S. biofertility product, we are accelerating our mission to improve the global food system through sustainable production solutions.”

The Company continues to focus on strategic capital allocation to drive revenue growth in both its NexusBioAg Canadian distribution business and TerraSante™ biofertility sales in the United States.

In Q1-2025, MustGrow made several advancements:

• Secured access to additional agriculture products via the NexusBioAg platform
• Signed a five-year exclusive distribution agreement with Adjuvants Plus Inc., a Canadian regenerative agriculture company
• Expanded its product portfolio with three new biological solutions: EZ-Gro Max, EZ-Gro Cyto, and Rootella® mycorrhizal inoculants

MustGrow remains committed to bringing new and meaningful biological innovations to Canadian farmers. More information can be found on the NexusBioAg website.

⁽¹⁾ Gross margin is a non-IFRS financial measure. It expresses gross profit as a percentage of revenue for a given period and helps explain the Company’s profitability. It is calculated by dividing gross profit by revenue for the same period. There is no directly comparable IFRS measure.

Source – MustGrow